Solu-Cortef
Sandhoff Disease
Joanne Kurtzberg, MDPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Sandhoff Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2/3 | BB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Venglustat Genzyme, a Sanofi Company | Phase 3 | B |
Duoc-01 Joanne Kurtzberg, MD | Phase 1 | CC |
Same molecule, other indications
Solu-Cortef is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →